Wasatch Biolabs

Congratulations to our parent company, Renew Biotechnologies, for winning the BioTech Breakthrough Award for DNA Sequencing Innovation of the Year! #DNASequencing #Methylation #Epigenetics #Diagnostics #BiotechInnovation?

Wasatch Biolabs is excited to introduce MethylSeqR, an exclusive R package that makes native-read methylation data more accessible. With MethylSeqR, researchers can analyze methylation across the entire genome, covering up to 30X more CpG sites than traditional arrays. Designed to simplify the transition from methylation array to direct Whole Methylome Sequencing, MethylSeqR integrates seamlessly into existing array-based workflows. With no bioinformatics expertise required, users can perform key analyses with just four simple commands, including: —Methylation summary by base position or CpG Islands —Differential expression by region, read, or position —Sliding window analysis Only available to WBL clients, contact our team today to explore how MethylSeqR can be incorporated into your research projects! Link: https://lnkd.in/gB6nRYQz #MethylSeqR #directWholeMethylomeSequencing #Methylation #Epigenetics?

Excited to be featured on the Empowered Patient Podcast with Karen Jagoda! Unlike DNA sequence, which largely remains constant throughout life, epigenetic markers change due to aging, disease, and other factors, making them attractive diagnostic targets. Dr. Jonathon Hill, PhD explores the clinical potential of our novel DNA methylation technologies for early disease detection and other applications. Listen below or on any podcast streaming platform: https://lnkd.in/gscCwUEv #Diagnostics #EpigeneticMedicine #PrecisionMedicine #Diagnostics #AlzheimersDisease #DNASequencing #Methylation #OxfordNanoporeTechnologies #NativeSequencing

A big thank you to Dasha Tyshlek for hosting us on the Biomedical Frontiers Podcast! In this episode, Dr. Jonathon Hill, PhD, Wasatch Biolabs Co-Founder, dives into our proprietary methylation technologies and their potential to accelerate biomarker discovery and clinical impact through partnerships across therapeutic areas. Tune in at the link below or on any other podcast platform: https://lnkd.in/gtez3fVT #Methylation #NanoporeSequencing #NativeSequencing #ClinicalEpigenomics #BiomarkerDiscovery?

Big milestone for Wasatch Biolabs! Looking forward to future breakthroughs in methylation research and clinical epigenomics. https://lnkd.in/ePyqZGf8 #Innovation #Methylation #Research #ClinicalEpigenomics

Thrilled about the innovation this collaboration with Oxford Nanopore Technologies will bring! Join us for our joint WBL x Oxford Nanopore CoLab session at the upcoming Annual Meeting of the American Society of Human Genetics in Denver. Date and time: Nov 6th at 12pm MT Location: Colab Theater #1 WBL Booth: #404 #DirectWholeMethylomeSequencing #ClinicalEpigenomics #DNA #Sequencing #Nanopore #Innovation

Our CEO, Chad Pollard, had the exciting opportunity to showcase?Wasatch Biolabs proprietary sequencing technology at Oxford Nanopore Technologies #NCM2024 meeting! Chad's talk highlighted some of WBL's novel methylation assays and their potential in biomarker discovery and clinical diagnostics, with a focus on tests for neurodegenerative disease screening and male infertility. Watch the full presentation https://lnkd.in/dQaASH5j or visit www.wasatchbiolabs.com to learn how WBL’s technology is shaping the future of epigenetic research and precision diagnostics. #NanoporeConf #BioPharmaDay #Methylation #DNASequencing #PrecisionMedicine

Unlock the Full Potential of Liquid Biopsies! Cell-free DNA-based liquid biopsies have incredible diagnostic potential. However, research tools and clinical applications have been hindered by the challenge of highly fragmented, low concentration cfDNA. To solve this and bypass the limitations of traditional bisulfate sequencing, WBL has developed NESSI-Seq, a novel sequencing technique that preserves DNA in its native state to produce genomic and epigenomic data with unparalleled accuracy, sensitivity, and quality. Check-out our most recent white-paper to learn more!

Next generation sequencing (NGS) liquid biopsies are transforming clinical diagnostics. Circulating cell-free DNA (cfDNA) is a particularly versatile target for liquid biopsies, with rapidly expanding use cases for cancer, prenatal testing, pathogen detection, and beyond. But despite advancements in NGS technologies and DNA analysis, cfDNA-based liquid biopsies are significantly limited by low specificity, sensitivity, and complicated data interpretation. Check out our latest article exploring the pivotal role of NGS in liquid biopsies. We dive into the technological advancements propelling the global NGS market and precision medicine, examine future clinical outlooks, and discuss current limitations. This sets the stage to introduce Wasatch Biolabs' proprietary sequencing technologies. Find the full article here: https://lnkd.in/gvMJXEHJ #PrecisionMedicine #LiquidBiopsy #WBL #NGS #cfDNA #OxfordNanoporeTechnology

Come join the WBL team at Oxford Nanopore Technologies's BioPharma Day! Our Co-Founder and CEO, Chad Pollard, will highlight WBL's pivotal role in the clinical integration of genetic and epigenetic biomarkers, revolutionizing diagnostics and precision medicine. Despite advancements in sequencing technology, current DNA methylation analysis faces challenges like obscured biological signals, amplification biases, and chemical DNA damage. We're excited to share our Nanopore-powered solution. Register now to join us for a day filled with innovation and knowledge sharing: https://lnkd.in/gvPru9sH Location: Boston Public Library Date : Wednesday, September 18 Time : 9:00 am - 5:00 pm Cost : FREE but registration required